Canada · Delayed Price · Currency is CAD PharmaCielo Statistics
Total Valuation
PharmaCielo has a market cap or net worth of CAD 13.73 million. The enterprise value is 31.87 million.
| Market Cap | 13.73M |
| Enterprise Value | 31.87M |
Important Dates
The next estimated earnings date is Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PharmaCielo has 211.28 million shares outstanding. The number of shares has increased by 8.09% in one year.
| Current Share Class | 211.28M |
| Shares Outstanding | 211.28M |
| Shares Change (YoY) | +8.09% |
| Shares Change (QoQ) | +1.06% |
| Owned by Insiders (%) | 14.68% |
| Owned by Institutions (%) | 0.15% |
| Float | 180.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.41 |
| PB Ratio | -1.25 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 12.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15
| Current Ratio | 0.15 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.94 |
| Interest Coverage | -1.39 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -12.82% |
| Return on Invested Capital (ROIC) | -20.02% |
| Return on Capital Employed (ROCE) | 30.41% |
| Weighted Average Cost of Capital (WACC) | 9.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.16 |
| Inventory Turnover | 1.09 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +44.44% in the last 52 weeks. The beta is 0.59, so PharmaCielo's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | +44.44% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 47.25 |
| Average Volume (20 Days) | 24,845 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaCielo had revenue of CAD 2.54 million and -3.58 million in losses. Loss per share was -0.02.
| Revenue | 2.54M |
| Gross Profit | 725,209 |
| Operating Income | -3.19M |
| Pretax Income | -3.58M |
| Net Income | -3.58M |
| EBITDA | -2.60M |
| EBIT | -3.34M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 17,517 in cash and 18.16 million in debt, with a net cash position of -18.14 million or -0.09 per share.
| Cash & Cash Equivalents | 17,517 |
| Total Debt | 18.16M |
| Net Cash | -18.14M |
| Net Cash Per Share | -0.09 |
| Equity (Book Value) | -10.98M |
| Book Value Per Share | -0.05 |
| Working Capital | -19.99M |
Cash Flow
| Operating Cash Flow | -4.61M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.40M |
| Net Borrowing | -5.44M |
| Free Cash Flow | -4.61M |
| FCF Per Share | -0.02 |
Margins
Gross margin is 28.59%, with operating and profit margins of -125.75% and -141.06%.
| Gross Margin | 28.59% |
| Operating Margin | -125.75% |
| Pretax Margin | -141.06% |
| Profit Margin | -141.06% |
| EBITDA Margin | -102.40% |
| EBIT Margin | -131.68% |
| FCF Margin | n/a |
Dividends & Yields
PharmaCielo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.09% |
| Shareholder Yield | -8.09% |
| Earnings Yield | -26.05% |
| FCF Yield | -33.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 18, 2019. It was a reverse split with a ratio of 0.083752.
| Last Split Date | Jan 18, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.083752 |
Scores
PharmaCielo has an Altman Z-Score of -26.03 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -26.03 |
| Piotroski F-Score | 2 |